Munich appeals court paves the way for MSD’s Keytruda SC in Germany
The dispute between Halozyme and Merck Sharp & Dohme and its European affiliates centres on Halozyme’s European patent EP 2 797 622. It protects a polypeptide variant underlying the subcutaneous formulation of pembrolizumab.